Changes in U.S. Prescribing Patterns of Menopausal Hormone Therapy, 2001–2003

Hing, Esther; Brett, Kate M.

doi:10.1097/01.aog.0000220502.77153.5a

Cited by 61 publications

(41 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The largest decrease in visits was for combined estrogen-progestin therapy, which dropped from 2% of visits in 2001 to 1.3% in 2003 (28). Data from two prescription-based databases indicate that the total number of women using any type of hormone therapy in the United States dropped from 15 million in 1999 to 10 million in 2003 (29). Prescriptions for the most common oral drug brand of estrogenprogestin dropped about 66% in the time period from July 2002 to July 2003 (29).…”

Section: Introductionmentioning

confidence: 99%

The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004

Eheman¹,

Shaw²,

Ryerson

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: National incidence rates for lobular and ductal breast cancers have not been available previously. Evidence suggests that the increased risk of breast cancer associated with combined hormone replacement therapy use is higher for invasive lobular cancers (ILC) than for invasive ductal cancers (IDC). This study provides U.S. incidence rates for these histologic types for both in situ and invasive cancers and assesses changes in the incidence of these cancers over time. Methods: Data for this study included incident ductal and lobular breast cancer cases diagnosed from 1999 through 2004 in central cancer registries in 44 states and the District of Columbia from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results program. We estimated incidence per 100,000 women by 10-year age groups, race, and eth-

show abstract

Section: Introductionmentioning

confidence: 99%

The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004

Eheman¹,

Shaw²,

Ryerson

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…In the 1980's estrogen began to be prescribed as a prophylactic against osteoporosis when it was shown to reduce fractures (Weiss, Ure et al 1980;Kiel, Felson et al 1987) and was thought to be potentially beneficial against other chronic illnesses such as heart disease and dementia (Bluming and Tavris 2009). A sharp decline in prescription of HRT occurred after the termination of the combination estrogen-progestin therapy arm of the Women's Health Initiative (WHI) in 2002 (Hing and Brett 2006). Since 2002 the WHI has made a number of updated reports warning of the dangers of HRT, however careful review of the data reveals these dangers are largely unfounded in most women (Bluming and Tavris 2009).…”

Section: Menopause and Hormone Therapy Regimensmentioning

confidence: 99%

Modulation of Immune Senescence by Menopause and Hormone Therapy

Engelmann¹,

Asquith²,

Messaoudi³

2012

Sex Steroids

View full text Add to dashboard Cite

“…Evidence from records of prescriptions filled, physician visits (Hersh et al, 2004;Hing & Brett, 2006), observational studies (Bruist et al, 2004;Ettinger, Grady, Tosteson, Pressman, & Macer, 2003;Haas, Kaplan, Gerstenberger, & Kerlikowske, 2004;Schonberg, Davis, & Wee, 2005) and a national telephone survey (Kelly et al, 2005) indicates a reduction in the use of postmenopausal HT after the recommendation changes, but these estimates have not been based on nationally representative samples or well-specified data on menopausal status and social characteristics.…”

Section: Changes In the Use Of Postmenopausal Ht Over Timementioning

confidence: 99%